Protea Biosciences Group, Inc. (OTCQB: PRGB) is a leader in the emerging field of Bioanalytics. The company develops new technology for the identification, characterization, and quantitation of biologically-important molecules for basic research, pharmaceutical development, and diagnostic applications. Bioanalytics is the direct identification and characterization of the products of all living cells, including proteins, lipids, metabolites and nucleic acids. Bioanalytics is emerging as a crucial area, where new technology is needed to support the future of medical research, and virtually every other field of life science research. SNNLive spoke with Stephen Turner, Chairman and CEO of Protea Biosciences Group, Inc. at the LD Micro "Main Event" 2014 in Bel Air, CA.
Mr. Turner begins with an overview of the company, “Protea developed a completely revolutionary molecular technology. It allows people for the first time to look at cells and tissue and drug discovery and diagnostics and see hundreds, if not over a thousand, of the different molecules that are being produced by those cells. Now that may not sound important, but all of the decisions you make in drug discovery, all of the decisions you make as a pathologist, as a doctor looking at treatment are based on the data, are based on the molecular evidence of what’s going on in those cells in that person.”
He discusses where the technology is from, “It’s a brilliant technology, we licensed it from George Washington University and spent a lot of time and a lot of money developing it and now bringing it to market, but first of all it’s very rapid, you never have to touch the sample, you can generate these molecular profiles as we like to call them, within a matter of minutes to an hour and the beauty of it is you do it without ever touching the sample.” For more information, check out their website: www.ProteaBio.com
© 2017 Stock News Now
Supported by Superior Web Solutions